News|Articles|November 18, 2026

Trump Pulls Overton's FDA Nomination Ahead of Senate HELP Vote

Listen
0:00 / 0:00

Key Takeaways

  • Withdrawal followed fragile HELP Committee dynamics, where a single Republican defection could sink confirmation amid broader post-midterm political recalibration.
  • Vaccine policy alignment with an executive order reducing routine childhood immunizations and separating MMR doses triggered backlash from medical groups and FDA career staff.
SHOW MORE

The White House pulled Heidi Overton's FDA nomination a day before a Senate HELP vote, leaving acting Commissioner Kyle Diamantas in charge.

The White House has pulled Heidi Overton's nomination for FDA commissioner after it failed to draw enough backing in Congress, three sources told Reuters.1 The Senate Health, Education, Labor and Pensions (HELP) Committee had been set to take up her nomination on Nov. 18.

The GOP holds a one-seat majority on the committee, meaning opposition from any single Republican member would put the nomination at risk.1 Sen. Roger Marshall of Kansas, an obstetrician by training whose own reelection bid failed this month, is under consideration to replace Overton, two of the sources said.1 In the meantime, Kyle Diamantas, the FDA's deputy commissioner for food, continues to run the agency on an acting basis.

Why Did Overton's Nomination Lose Support?

Some administration officials handling the nomination grew skeptical that Senate Republicans would back Overton after the party lost its House and Senate majorities in the November midterms, Reuters reported.1 The defeats extended to the HELP Committee, where Marshall, Sen. Susan Collins and outgoing Chairman Bill Cassidy (R-La.), a physician, all lost their races. GOP senators had nonetheless been rounding up votes for her for several days before the scheduled vote.1

Cassidy had not fully committed to backing Overton, and had previously faulted her for participation in the administration's push to scale back childhood vaccinations.1 Overton appeared alongside Trump on Aug. 10 as he signed an executive order aimed at reducing the standard childhood vaccine schedule from 18 to 11 shots and splitting the measles, mumps and rubella (MMR) vaccine into separate doses.2 Reportedly, her backing of the order alarmed a number of medical organizations and career FDA staff.1

On the Democratic side, objections centered on mifepristone. Overton has previously spoken out against the Biden administration's decision to ease restrictions on how the drug is dispensed.1 She also faced pushback from prominent backers of HHS secretary Robert F. Kennedy Jr.'s "Make America Healthy Again" movement, who took issue with her links to companies they oppose.1

Vaping was another flashpoint. At her confirmation hearing in September, Overton defended the FDA's decision in May to authorize fruit-flavored e-cigarettes, pointing to evidence that the products may help some adult smokers quit.1 Since then, groups have advocated against her ahead of her hearing.

What Does Prolonged Temporary Leadership Mean for the FDA?

Overton, a preventive medicine physician who serves as deputy director of the White House Domestic Policy Council, was tapped in August, three months after Marty Makary stepped down as commissioner.1

Overton was the administration's third choice for the role; former Rep. Brad Wenstrup (R-Ohio) declined the position and Diamantas reportedly passed on it, Pharmaceutical Commerce reported at the time.2 More than 4,500 employees have left the FDA over the past year, Reuters reported.1

Makary's tenure was marked by reversals that industry executives said disrupted the predictability drugmakers rely on for review timelines, including rejection letters for therapies that had previously received preliminary FDA support.2 Since Diamantas took over, the FDA has reversed course or reopened regulatory paths for rare-disease therapies from Regenxbio, uniQure and Replimune, and launched a program pairing drug sponsors with research institutions to shorten the time from drug identification to first-in-human studies.2

The FDA is also conducting a safety review of mifepristone, with Republicans pushing to reverse a Biden-era rule allowing the drug to be mailed and dispensed via telehealth.2 The agency has said it expects to finish that review by March 2027.1

References

1. Bogage, Jacob, Ahmed Aboulenein and Yasmeen Abutaleb. "Trump withdraws Heidi Overton as nominee to lead Food and Drug Administration, sources say." Reuters. Published Nov. 17, 2026. Accessed Nov. 18, 2026. https://www.reuters.com/legal/litigation/trump-withdraws-heidi-overton-nominee-lead-food-drug-administration-sources-say-2026-11-18/

2. "Trump Expected to Tap Heidi Overton as FDA Commissioner." Pharmaceutical Commerce. Published Aug. 19, 2026. Accessed Nov. 18, 2026. https://www.pharmaceuticalcommerce.com/view/heidi-overton-expected-to-lead-fda?ekey=c2FwcGV6emF0b0BtamhsaWZlc2NpZW5jZXMuY29t


Related to this article